Page 17 - AN-1-1

Advanced Neurology AIS in patients with COVID-19

Table 3. Characteristics and outcomes of acute ischemic stroke patients with COVID-19.
Variables No. of Proportion (95%CI) or pooled Proportion (95%CI) or I 2 heterogeeneity (%) P heterogeeneity
studies median Random effects pooled median Fixed effects
Demographics
Age 30 66.450 (64.569, 68.330) 68.832 (68.431, 69.234) 92.9 <0.0001***
Gender (male) 33 0.646 (0.606, 0.687) 0.583 (0.570, 0.597) 80.4 <0.0001***
Stroke subtype (TOAST)
Small vessel 19 0.076 ( 0.048, 0.103) 0.051 (0.037, 0.065) 64.5 <0.0001***
Large artery atherosclerosis 18 0.139 (0.097, 0.181) 0.109 (0.089, 0.129) 72.9 <0.0001***
Cardioembolic 18 0.264 (0.205, 0.324) 0.219 (0.192, 0.245) 76.3 <0.0001***
Other known cause 16 0.051 (0.030, 0.072) 0.036 (0.023, 0.049) 47.8 0.017*
Cryptogenic 17 0.410 (0.339, 0.480) 0.392 (0.359, 0.425) 76.1 <0.0001***
Stroke territories
Anterior circulation 7 0.866 (0.765, 0.966) 0.930 (0.892, 0.968) 73.5 0.002**
MCA 10 0.456 (0.332, 0.581) 0.390 (0.338, 0.441) 79.8 <0.0001***
ICA 8 0.204 (0.109, 0.298) 0.141 (0.099, 0.182) 73.0 0.001**
Posterior circulation 7 0.067 (0.030, 0.104) 0.067 (0.030, 0.104) 0 0.557
Multiple territories 5 0.303 (0.172, 0.434) 0.250 (0.192, 0.308) 76.0 0.002**
Laboratory findings
CRP (mg/L) 14 108.778 (77.845,139.711) 22.422 (19.568, 25.277) 97.0 <0.0001***
WBC (×10 /µL) 12 9.242 (8.618, 9.866) 9.037 (8.767, 9.306) 75.6 <0.0001***
3
PLT (×10 /µL) 16 244.664 (231.336, 257.992) 236.337 (229.980, 242.694) 71.1 <0.0001***
3
Other stroke characteristics
NIHSS at admission 24 13.113 (11.717, 14.509) 10.936 (10.539, 11.332) 88.4 <0.0001***
Large vessel occlusion 13 0.406 (0.332, 0.481) 0.304 (0.282, 0.326) 76.5 <0.0001***
Volume of infarction (cm ) 2 47.536 (9.857, 85.215) 37.324 (22.964, 51.684) 66.3 0.085
3
ASPECT score 5 7.867 (6.533, 9.200) 8.853 (8.419, 9.287) 85.6 <0.0001***
Overall outcomes of AIS
HT 11 0.132 (0.085, 0.180) 0.048 (0.040, 0.056) 86.1 <0.0001***
sICH 9 0.046 (0.017, 0.075) 0.030 (0.013, 0.047) 40.2 0.100
In-hospital mortality 28 0.292 (0.244, 0.339) 0.225 (0.211, 0.239) 82.9 <0.0001***
Favorable discharge 14 0.290 (0.238, 0.342) 0.287 (0.253, 0.321) 49.5 0.018*
Outcomes following IVT
HT 2 0.255 (0.124, 0.386) 0.234 (0.158, 0.310) 33.9 0.219
sICH 3 0.074 (0.031, 0.118) 0.074 (0.031, 0.118) 0 0.660
In-hospital mortality 2 0.252 (0.175, 0.328) 0.252 (0.175, 0.328) 0 0.762
Favorable discharge 2 0.266 (0.163, 0.369) 0.256 (0.179, 0.333) 22.5 0.256
Outcomes following MT
HT 1 - - - -
sICH 5 0.042 (−0.009, 0.093) 0.024 (−0.006, 0.053) 21.3 0.279
In-hospital mortality 6 0.288 (0.206, 0.370) 0.220 (0.203, 0.237) 61.9 0.022*
Favorable discharge 2 0.325 (0.014, 0.635) 0.410 (0.324, 0.496) 87.7 0.004**
ASPECTS, Alberta Stroke Program Early CT Score; CI, confidence intervals; CRP, C-reactive protein; HT, hemorrhagic transformation; ICA, internal
carotid artery; IVT, intravenous thrombolysis; MCA, middle cerebral artery; MT, mechanical thrombectomy; NIHSS, National Institutes of Health
Stroke Scale; PLT, platelets; sICH, symptomatic intracerebral hemorrhage; TOAST, Trial of Org 10172 in Acute Stroke Treatment; WBC, white blood
cell count. *P < 0.05, **P < 0.005, ***P < 0.001.

Volume 1 Issue 1 (2022) 9 https://doi.org/10.36922/an.v1i1.28